Oragenics receives clearance to enroll patients in Germany and UK into phase 2 trial
Oragenics announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute and patients residing in the UK from the MHRA, into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM. November 15, 2018